The most common arrhythmias detected during pregnancy include sinus tachycardia, sinus bradycardia, and sinus arrhythmia, identified in 0.1% of pregnancies. Isolated premature atrial or ventricular arrhythmias are observed in 0.03% of pregnancies. Arrhythmias may become more frequent during pregnancy or may manifest for the first time.
BrugadaPBrugadaJMontL, et al.
A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation1991;
83: 1649–1659.
2.
VereckeiADurayGSzénásiG, et al.
New algorithm using only lead aVR for differential diagnosis of wide QRS complex tachycardia. Heart Rhythm2008;
5: 89–98.
3.
LiJ-MNguyenCJoglarJA, et al.
Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service. Clin Cardiol2008;
31: 538–541.
4.
LeeSHChenSAWuTJ, et al.
Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol1995;
76: 675–678.
5.
BánhidyFÁcsNPuhóEH, et al.
Paroxysmal supraventricular tachycardia in pregnant women and birth outcomes of their children: a population-based study. Am J Med Genet A2015;
167A: 1779–1786.
6.
SilversidesCKHarrisLHabererK, et al.
Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol2006;
97: 1206–1212.
7.
CarruthJEMivisSBBroganDR, et al.
The electrocardiogram in normal pregnancy. Am Heart J1981;
102: 1075–1078.
8.
ClappJFCapelessE.Cardiovascular function before, during, and after the first and subsequent pregnancies. Am J Cardiol1997;
80: 1469–1473.
9.
GrindheimGEstensenM-ELangesaeterE, et al.
Changes in blood pressure during healthy pregnancy: a longitudinal cohort study. J Hypertens2012;
30: 342–350.
10.
PeyrolMLévyS.Clinical presentation of inappropriate sinus tachycardia and differential diagnosis. J Interv Card Electrophysiol2016;
46: 33–41.
11.
SheldonRSGrubbBPOlshanskyB, et al.
2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm2015;
12: e41–63.
12.
PageRLJoglarJACaldwellMA, et al.
2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm2016;
13: e136–221.
13.
KockovaRSvatunkovaJNovotnyJ, et al.
Heart rate changes mediate the embryotoxic effect of antiarrhythmic drugs in the chick embryo. Am J Physiol Heart Circ Physiol2013;
304: H895–902.
14.
LeonelliFBaglianiGBorianiG, et al.
Arrhythmias originating in the Atria. Card Electrophysiol Clin2017;
9: 383–409.
CollinsKKVan HareGFKerteszNJ, et al.
Pediatric nonpost-operative junctional ectopic tachycardia medical management and interventional therapies. J Am Coll Cardiol2009;
53: 690–697.
17.
RuderMADavisJCEldarM, et al.
Clinical and electrophysiologic characterization of automatic junctional tachycardia in adults. Circulation1986;
73: 930–937.
18.
MillerJM.Therapy of Wolff-Parkinson-White syndrome and concealed bypass tracts: part I. J Cardiovasc Electrophysiol1996;
7: 85–93.
LimaFVKoutrolou-SotiropoulouPYenTYM, et al.
Clinical characteristics and outcomes in pregnant women with Ebstein anomaly at the time of delivery in the USA: 2003–2012. Arch Cardiovasc Dis2016;
109: 390–398.
21.
WaxmanMBWaldRWSharmaAD, et al.
Vagal techniques for termination of paroxysmal supraventricular tachycardia. Am J Cardiol1980;
46: 655–664.
22.
LimSHAnantharamanVTeoWS, et al.
Comparison of treatment of supraventricular tachycardia by Valsalva maneuver and carotid sinus massage. Ann Emerg Med1998;
31: 30–35.
23.
ÇorbacıoğluŞKAkıncıEÇevikY, et al.
Comparing the success rates of standard and modified Valsalva maneuvers to terminate PSVT: a randomized controlled trial. Am J Emerg Med2017;
35:1662–1665.
24.
WayneMA.Conversion of paroxysmal atrial tachycardia by facial immersion in ice water. JACEP1976;
5: 434–435.
25.
ElkayamUGoodwinTM.Adenosine therapy for supraventricular tachycardia during pregnancy. Am J Cardiol1995;
75: 521–523.
26.
RankinACOldroydKGChongE, et al.
Value and limitations of adenosine in the diagnosis and treatment of narrow and broad complex tachycardias. Br Heart J1989;
62: 195–203.
27.
BelardinelliLShryockJCSongY, et al.
Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. Faseb J1995;
9: 359–365.
28.
Kazemzadeh-NarbatMAnnabiNTamayolA, et al.
Adenosine-associated delivery systems. J Drug Target2015;
23: 580–596.
29.
LefflerSJohnsonDR.Adenosine use in pregnancy: lack of effect on fetal heart rate. Am J Emerg Med1992;
10: 548–549.
30.
HagleyMTColePL.Adenosine use in pregnant women with supraventricular tachycardia. Ann Pharmacother1994;
28: 1241–1242.
31.
JoglarJAPageRL.Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf1999;
20: 85–94.
32.
MatsubaraSKuwataTMitsuhashiT.Adenosine for maternal supraventricular tachycardia and preterm delivery. J Obstet Gynaecol Can2011;
33: 794–795; author reply 795.
33.
Regitz-ZagrosekVBlomstrom LundqvistCBorghiC, et al.
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J2018;
39: 3165–3241.
34.
SoykaLF.Digoxin: placental transfer, effects on the fetus, and therapeutic use in the newborn. Clin Perinatol1975;
2: 23–35.
35.
AllenNMPageRL.Procainamide administration during pregnancy. Clin Pharm1993;
12: 58–60.
36.
TimmisADJacksonGHoltDW.Mexiletine for control of ventricular dysrhythmias in pregnancy. Lancet1980;
2: 647–648.
37.
LownesHEIvesTJ.Mexiletine use in pregnancy and lactation. Am J Obstet Gynecol1987;
157: 446–447.
38.
MitaniGMSteinbergILienEJ, et al.
The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation. Clin Pharmacokinet1987;
12: 253–291.
39.
ChauveauSLe VavasseurOMorelE, et al.
Flecainide is a safe and effective treatment for pre-excited atrial fibrillation rapidly conducted to the ventricle in pregnant women: a case series. Eur Heart J Case Rep2019;
3: pii: ytz066.
40.
VillanovaCMuriagoMNavaF.Arrhythmogenic right ventricular dysplasia: pregnancy under flecainide treatment. G Ital Cardiol1998;
28: 691–693.
41.
ConnaughtonMJenkinsBS.Successful use of flecainide to treat new onset maternal ventricular tachycardia in pregnancy. Br Heart J1994;
72: 297.
42.
SubediRDeanRKChaudharyA, et al.
Flecainide toxicity in renal failure. Proc (Bayl Univ Med Cent)2018;
31: 328–330.
43.
D’AndreaALimongelliGCasoP, et al.
Association between left ventricular structure and cardiac performance during effort in two morphological forms of athlete’s heart. Int J Cardiol2002;
86: 177–184.
44.
BatemanBTPatornoEDesaiRJ, et al.
Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics2016;
138: pii: e20160731.
45.
Meidahl PetersenKJimenez-SolemEAndersenJT, et al.
β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open2012;
2: pii: e001185.
46.
ErsbøllASHedegaardMSøndergaardL, et al.
Treatment with oral beta-blockers during pregnancy complicated by maternal heart disease increases the risk of fetal growth restriction. BJOG2014;
121: 618–626.
47.
LydakisCLipGYBeeversM, et al.
Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens1999;
12: 541–547.
48.
LipGYBeeversMChurchillD, et al.
Effect of atenolol on birth weight. Am J Cardiol1997;
79: 1436–1438.
49.
EyalSKimJDAndersonGD, et al.
Atenolol pharmacokinetics and excretion in breast milk during the first 6 to 8 months postpartum. J Clin Pharmacol2010;
50: 1301–1309.
50.
LwinEMPGerberCLeggettC, et al.
Estimation of atenolol transfer into milk and infant exposure during its use in lactating women. J Hum Lact2018;
34: 592–599.
51.
KhuranaRBin JardanYAWilkieJ, et al.
Breast milk concentrations of amiodarone, desethylamiodarone, and bisoprolol following short-term drug exposure: two case reports. J Clin Pharmacol2014;
54: 828–831.
52.
HoeltzenbeinMFietzAKKayserA, et al.
Pregnancy outcome after first trimester exposure to bisoprolol: an observational cohort study. J Hypertens2018;
36: 2109–2117.
53.
KayserABeckEHoeltzenbeinM, et al.
Neonatal effects of intrauterine metoprolol/bisoprolol exposure during the second and third trimester: a cohort study with two comparison groups. J Hypertens2020;
38: 354–361.
54.
TanakaKTanakaHKamiyaC, et al.
Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J2016;
80: 2221–2226.
55.
RyuRJEyalSEasterlingTR, et al.
Pharmacokinetics of metoprolol during pregnancy and lactation. J Clin Pharmacol2016;
56: 581–589.
56.
PruynSCPhelanJPBuchananGC.Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol1979;
135: 485–489.
57.
O’HareMFKinneyCDMurnaghanGA, et al.
Pharmacokinetics of propranolol during pregnancy. Eur J Clin Pharmacol1984;
27: 583–587.
58.
BiswasMLevyAWeberR, et al.
Multicenter analysis of dosing protocols for sotalol initiation. J Cardiovasc Pharmacol Ther2019; 1074248419887710.
59.
ChungMKSchweikertRAWilkoffBL, et al.
Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol1998;
32: 169–176.
60.
HackettLPWojnar-HortonREDusciLJ, et al.
Excretion of sotalol in breast milk. Br J Clin Pharmacol1990;
29: 277–278.
61.
HallCMMcCormickKP.Amiodarone and breast feeding. Arch Dis Child Fetal Neonatal Ed2003;
88: F255–4.
62.
JavotLPapeEYéléhé-OkoumaM, et al.
Intravenous single administration of amiodarone and breastfeeding. Fundam Clin Pharmacol2019;
33: 367–372.
63.
McKennaWJHarrisLRowlandE, et al.
Amiodarone therapy during pregnancy. Am J Cardiol1983;
51: 1231–1233.
64.
Miller MR, Withers R, Bhamra R, Holt DW. Verapamil and breast-feeding. Eur J Clin Pharmacol 1986; 30: 125--126.
65.
KleinVRepkeJT.Supraventricular tachycaria in pregnancy: cardioversion with verapamil. Obstet Gynecol1984;
63: 16S–18S.
66.
SteinGSrivastavaMKMerkerHJ, et al.
Effects of calcium channel blockers on the development of early rat postimplantation embryos in culture. Arch Toxicol1990;
64: 623–638.
67.
ChaffmanMBrogdenRN.Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs1985;
29: 387–454.
68.
ZaidiASharmaS.Exercise and heart disease: from athletes and arrhythmias to hypertrophic cardiomyopathy and congenital heart disease. Future Cardiol2013;
9: 119–136.
69.
MadsenCDPointerJELynchTG.A comparison of adenosine and verapamil for the treatment of supraventricular tachycardia in the prehospital setting. Ann Emerg Med1995;
25: 649–655.
70.
BradyWJDeBehnkeDJWickmanLLLindbeckG.Treatment of out-of-hospital supraventricular tachycardia: adenosine vs verapamil. Acad Emerg Med1996;
3: 574–585.
71.
LimSHAnantharamanVTeoWS.Slow-infusion of calcium channel blockers in the emergency management of supraventricular tachycardia. Resuscitation2002;
52: 167–174.
72.
LimSHAnantharamanVTeoWS, et al.
Slow infusion of calcium channel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia. Resuscitation2009;
80: 523–528.
73.
KonishiHFukuzawaKMoriS, et al.
Anti-mitochondrial M2 antibodies enhance the risk of supraventricular arrhythmias in patients with elevated hepatobiliary enzyme levels. Intern Med2017;
56: 1771–1779.
74.
Cummins LancasterMSobieEA.Improved prediction of drug-induced Torsades de Pointes through simulations of dynamics and machine learning algorithms. Clin Pharmacol Ther2016;
100: 371–379.
75.
MauritsonDRWinnifordMDWalkerWS, et al.
Oral verapamil for paroxysmal supraventricular tachycardia: a long-term, double-blind randomized trial. Ann Intern Med1982;
96: 409–412.
76.
WinnifordMDFultonKLHillsLD.Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol1984;
54: 1138–1139.
77.
GoyJJFromerM.Antiarrhythmic treatment of atrioventricular tachycardias. J Cardiovasc Pharmacol1991;
17: S36–40.
78.
HenthornRWWaldoALAndersonJL, et al.
Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Circulation1991;
83: 119–125.
79.
AndersonJLPlattMLGuarnieriT, et al.
Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. Am J Cardiol1994;
74: 578–584.
80.
DorianPNaccarelliGVCoumelP, et al.
A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. Am J Cardiol1996;
77: 89A–95A.
81.
TenderaMWnuk-WojnarAMKulakowskiP, et al.
Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am Heart J2001;
142: 93–98.
82.
Group UKPPSVTS.A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation1995;
92: 2550–2557.
83.
PritchettELCDaTorreSDPlattML, et al.
Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. J Am Coll Cardiol1991;
17: 297–303.
84.
PritchettELCMcCarthyEAWilkinsonWE.Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: a randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med1991;
114: 539–544.
85.
AlabdulrazzaqFKorenG.Fetal safety of calcium channel blockers. Can Fam Physician2012;
58: 746–747.
86.
LinC-YLinY-JLoL-W, et al.
Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart. Heart Rhythm2015;
12: 1490–1500.
ReisingerJGstreinCWinterT, et al.
Optimization of initial energy for cardioversion of atrial tachyarrhythmias with biphasic shocks. Am J Emerg Med2010;
28: 159–165.
89.
RothAElkayamIShapiraI, et al.
Effectiveness of prehospital synchronous direct-current cardioversion for supraventricular tachyarrhythmias causing unstable hemodynamic states. Am J Cardiol2003;
91: 489–491.
90.
SauvéNReyÉCumynA.Atrial fibrillation in a structurally normal heart during pregnancy: a review of cases from a registry and from the literature. J Obstet Gynaecol Can2017;
39: 18–24.
91.
CammAJKirchhofPLipGYH, et al.
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace2010;
12: 1360–1420.
92.
MembersAFFusterVRydénLE, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J2006;
27: 1979–2030.
93.
KirchhofPBenussiSKotechaD, et al.
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace2016;
18: 1609–1678.
94.
HoeltzenbeinMBeckEMeixnerK, et al.
Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol2016;
105: 117–126.
95.
FrankelDSLinDAnastasioN, et al.
Frequent additional tachyarrhythmias in patients with inappropriate sinus tachycardia undergoing sinus node modification: an important cause of symptom recurrence. J Cardiovasc Electrophysiol2012;
23: 835–839.
96.
SegalJBMcNamaraRLMillerMR, et al.
The evidence regarding the drugs used for ventricular rate control. J Fam Pract2000;
49: 47.
97.
SiuC-WLauC-PLeeW-L, et al.
Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. Crit Care Med2009;
37: 2174–2179; quiz 2180.
98.
Briggs GgFRKTowersCVForinashAB.Drugs in pregnancy and lactation.
Alphen aan den Rijn:
Wolters Kluwer, 2017.
99.
BergerMSchweitzerP.Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol1998;
82: 1545–1547.
100.
DrenthenWPieperPGRoos-HesselinkJW, et al.
Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol2007;
49: 2303–2311.
101.
WarnesCAWilliamsRGBashoreTM, et al.
ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines for the management of adults with congenital heart disease). Circulation2008;
118: 2395–2451.
102.
KoyakZKroonBde GrootJR, et al.
Efficacy of antiarrhythmic drugs in adults with congenital heart disease and supraventricular tachycardias. Am J Cardiol2013;
112: 1461–1467.
103.
SalamAMErtekinEvan HagenIM, et al.
Atrial fibrillation or flutter during pregnancy in patients with structural heart disease: data from the ROPAC (Registry on Pregnancy and Cardiac Disease). Jacc Clin Electrophysiol2015;
1: 284–292.
104.
WalshEP.Interventional electrophysiology in patients with congenital heart disease. Circulation2007;
115: 3224–3234.
105.
JansonCMShahMJ.Supraventricular tachycardia in adult congenital heart disease: mechanisms, diagnosis, and clinical aspects. Card Electrophysiol Clin2017;
9: 189–211.
106.
WarnesCALiberthsonRDanielsonGK, et al.
Task force 1: the changing profile of congenital heart disease in adult life. J Am Coll Cardiol2001;
37: 1170–1175.
107.
StephensonEACasavantDTuziJ, et al.
Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. Am J Cardiol2003;
92: 871–876.
108.
KhairyPVan HareGFBalajiS, et al.
PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Can J Cardiol2014;
30: e1–e63.
109.
BremmeKA.Haemostatic changes in pregnancy. Best Pract Res Clin Haematol2003;
16: 153–168.
110.
FeltesTFFriedmanRA.Transesophageal echocardiographic detection of atrial thrombi in patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease. J Am Coll Cardiol1994;
24: 1365–1370.
111.
JensenASIdornLNøragerB, et al.
Anticoagulation in adults with congenital heart disease: the who, the when and the how?Heart2015;
101: 424–429.
112.
VosMAGolitsynSRStanglK, et al.
Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. Heart1998;
79: 568–575.
113.
PacificoAHohnloserSHWilliamsJH, et al.
Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med1999;
340: 1855–1862.
114.
HoyerAWBalajiS.The safety and efficacy of ibutilide in children and in patients with congenital heart disease. Pacing Clin Electrophysiol2007;
30: 1003–1008.
115.
RaoSOBoramanandNKBurtonDA, et al.
Atrial tachycardias in young adults and adolescents with congenital heart disease: conversion using single dose oral sotalol. Int J Cardiol2009;
136: 253–257.
116.
GowdaRMKhanIAPunukolluG, et al.
Female preponderance in ibutilide-induced torsade de pointes. Int J Cardiol2004;
95: 219–222.
117.
KhairyPFernandesSMMayerJE, et al.
Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation2008;
117: 85–92.
118.
KhairyPHarrisLLandzbergMJ, et al.
Sudden death and defibrillators in transposition of the great arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm Electrophysiol2008;
1: 250–257.
119.
ArenalAOrtizMPeinadoR, et al.
Differentiation of ventricular and supraventricular tachycardias based on the analysis of the first postpacing interval after sequential anti-tachycardia pacing in implantable cardioverter-defibrillator patients. Heart Rhythm2007;
4: 316–322.
120.
CalòLDe RuvoESetteA, et al.
Tachycardia-induced cardiomyopathy: mechanisms of heart failure and clinical implications. J Cardiovasc Med (Hagerstown)2007;
8: 138–143.
121.
Della RoccaDGSantiniLForleoGB, et al.
Novel perspectives on arrhythmia-induced cardiomyopathy: pathophysiology, clinical manifestations and an update on invasive management strategies. Cardiol Rev2015;
23: 135–141.
122.
RoyDTalajicMNattelS, et al.
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med2008;
358: 2667–2677.
123.
HohnloserSHKuckKHLilienthalJ.Rhythm or rate control in atrial fibrillation – pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet2000;
356: 1789–1794.
124.
SkanesACHealeyJSCairnsJA, et al.
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol2012;
28: 125–136.
125.
AndersonJLHalperinJLAlbertNM, et al.
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations). J Am Coll Cardiol2013;
61: 1935–1944.
126.
FishFAGillettePCBensonDW; Group TPE.Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. J Am Coll Cardiol1991;
18: 356–365.
127.
Beaufort-KrolGCBink-BoelkensMT.Sotalol for atrial tachycardias after surgery for congenital heart disease. Pacing Clin Electrophysiol1997;
20: 2125–2129.
128.
FreemantleNLafuente-LafuenteCMitchellS, et al.
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace2011;
13: 329–345.
129.
Lafuente-LafuenteCLongas-TejeroMABergmannJ-F, et al.
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev2012; (3): CD005049.
130.
ThorneSABarnesICullinanP, et al.
Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Circulation1999;
100: 149–154.
131.
RoyDTalajicMDorianP, et al.
Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med2000;
342: 913–920.
132.
MageeLADownarESermerM, et al.
Pregnancy outcome after gestational exposure to amiodarone in Canada. Am J Obstet Gynecol1995;
172: 1307–1311.
133.
LomenickJPJacksonWABackeljauwPF.Amiodarone-induced neonatal hypothyroidism: a unique form of transient early-onset hypothyroidism. J Perinatol2004;
24: 397–399.
134.
BartalenaLBogazziFBravermanLE, et al.
Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest2001;
24: 116–130.
135.
MageeLANulmanIRovetJF, et al.
Neurodevelopment after in utero amiodarone exposure. Neurotoxicol Teratol1999;
21: 261–265.
136.
VorperianVRHavighurstTCMillerS, et al.
Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol1997;
30: 791–798.
137.
HohnloserSHKlingenhebenTSinghBN.Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern Med1994;
121: 529–535.
138.
EpsteinAEDiMarcoJPEllenbogenKA, et al.
ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol2012;
61: e6–75.
139.
Torp-PedersenCMøllerMBloch-ThomsenPE, et al.
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med1999;
341: 857–865.
140.
KalusJSMauroVF.Dofetilide: a class III-specific antiarrhythmic agent. Ann Pharmacother2000;
34: 44–56.
141.
KøberLThomsenPEBMøllerM, et al.
Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet2000;
356: 2052–2058.
142.
PedersenODBaggerHKellerN, et al.
Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation2001;
104: 292–296.
143.
SinghSZobleRGYellenL, et al.
Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation2000;
102: 2385–2390.
144.
WellsRKhairyPHarrisL, et al.
Dofetilide for atrial arrhythmias in congenital heart disease: a multicenter study. Pacing Clin Electrophysiol2009;
32: 1313–1318.
145.
AbadirSKhairyP.Electrophysiology and adult congenital heart disease: advances and options. Prog Cardiovasc Dis2011;
53: 281–292.
146.
BrodskyMDoriaRAllenB, et al.
New-onset ventricular tachycardia during pregnancy. Am Heart J1992;
123: 933–941.
147.
Regitz-ZagrosekVBlomstrom LundqvistCBorghiC, et al.
ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J2011;
32: 3147–3197.
148.
GowdaRMPunukolluGKhanIA, et al.
Lone atrial fibrillation during pregnancy. Int J Cardiol2003;
88: 123–124.
149.
SliwaKHilfiker-KleinerDPetrieMC, et al.
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail2010;
12: 767–778.
150.
SliwaKHilfiker-KleinerDMebazaaA, et al.
EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. Eur J Heart Fail2014;
16: 583–591.
151.
CheitlinMDArmstrongWFAurigemmaGP, et al.
ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation2003;
108: 1146–1162.
152.
MiddlekauffHRStevensonWGStevensonLW, et al.
Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol1993;
21: 110–116.
153.
MaggioniAPZuanettiGFranzosiMG, et al.
Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation1993;
87: 312–322.
154.
MoradyFKadishAHDiCarloL, et al.
Long-term results of catheter ablation of idiopathic right ventricular tachycardia. Circulation1990;
82: 2093–2099.
155.
NakagawaMKatouSIchinoseM, et al.
Characteristics of new-onset ventricular arrhythmias in pregnancy. J Electrocardiol2004;
37: 47–53.
156.
ChunKRJSatomiKKuckK-H, et al.
Left ventricular outflow tract tachycardia including ventricular tachycardia from the aortic cusps and epicardial ventricular tachycardia. Herz2007;
32: 226–232.
157.
YamadaTMcElderryHTDoppalapudiH, et al.
Idiopathic ventricular arrhythmias originating from the aortic root: prevalence, electrocardiographic and electrophysiologic characteristics, and results of radiofrequency catheter ablation. J Am Coll Cardiol2008;
52: 139–147.
158.
TadaHHiratsujiTNaitoS, et al.
Prevalence and characteristics of idiopathic outflow tract tachycardia with QRS alteration following catheter ablation requiring additional radiofrequency ablation at a different point in the outflow tract. Pacing Clin Electrophysiol2004;
27: 1240–1249.
159.
LermanBB.Mechanism, diagnosis, and treatment of outflow tract tachycardia. Nat Rev Cardiol2015;
12: 597–608.
160.
SungRJKeungECNguyenNX, et al.
Effects of beta-adrenergic blockade on verapamil-responsive and verapamil-irresponsive sustained ventricular tachycardias. J Clin Invest1988;
81: 688.
161.
MarchlinskiFEDeelyMPZadoES.Sex-specific triggers for right ventricular outflow tract tachycardia. Am Heart J2000;
139: 1009–1013.
BurkeAPFarbASessumsL, et al.
Causes of sudden cardiac death in patients with replacement valves: an autopsy study. J Heart Valve Dis1994;
3: 10–16.
164.
OlafiranyeOHochreiterCABorerJS, et al.
Nonischemic mitral regurgitation: prognostic value of nonsustained ventricular tachycardia after mitral valve surgery. Cardiology2013;
124: 108–115.
165.
GrigioniFEnriquez-SaranoMLingLH, et al.
Sudden death in mitral regurgitation due to flail leaflet. J Am Coll Cardiol1999;
34: 2078–2085.
166.
VallesAGKhawajaFJGershBJ, et al.
Implantable cardioverter defibrillators in patients with valvular cardiomyopathy. J Cardiovasc Electrophysiol2012;
23: 1326–1332.
167.
SorgatoAFaggianoPAurigemmaGP, et al.
Ventricular arrhythmias in adult aortic stenosis: prevalence, mechanisms, and clinical relevance. Chest1998;
113: 482–491.
168.
PrioriSGBlomström-LundqvistCMazzantiA, et al.
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J2015;
36: 2793–2867.
169.
Mallikethi-ReddySAkintoyeETrehanN, et al.
Burden of arrhythmias in peripartum cardiomyopathy: analysis of 9841 hospitalizations. Int J Cardiol2017;
235: 114–117.
170.
KuckKH.Arrhythmias in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol1997;
20: 2706–2713.
171.
RomeroJMejia-LopezEManriqueC, et al.
Arrhythmogenic right ventricular cardiomyopathy (ARVC/D): a systematic literature review. Clin Med Insights Cardiol2013;
7: 97–114.
172.
Weissler-SnirACreanARakowskiH.The role of imaging in the diagnosis and management of hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther2016;
14: 51–74.
173.
GolandSvan HagenIMElbaz-GreenerG, et al.
Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). Eur Heart J2017;
38: 2683–2690.
174.
CozzolinoMPerelliFCorioniS, et al.
Successful obstetric management of arrhythmogenic right ventricular cardiomyopathy. Gynecol Obstet Invest2014;
78: 266–271.
175.
DoyleNMMongaMMontgomeryB, et al.
Arrhythmogenic right ventricular cardiomyopathy with implantable cardioverter defibrillator placement in pregnancy. J Matern Fetal Neonatal Med2005;
18: 141–144.
176.
AnouarJMohamedSKamelK.Management of a rare case of arrhythmogenic right ventricular dysplasia in pregnancy: a case report. Pan Afr Med J2014;
19: 246.
177.
HodesARTichnellCTe RieleA, et al.
Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart2016;
102: 303–312.
DaviesGALHerbertW.Ischemic heart disease and cardiomyopathy in pregnancy. J Obstet Gynaecol Can2007;
29: 575–579.
180.
Roos-HesselinkJWRuysTPESteinJI, et al.
Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J2013;
34: 657–665.
181.
ElkayamUJalnapurkarSBarakkatMN, et al.
Pregnancy-associated acute myocardial infarction: a review of contemporary experience in 150 cases between 2006 and 2011. Circulation2014;
129: 1695–1702.
182.
TweetMSHayesSNCodsiE, et al.
Spontaneous coronary artery dissection associated with pregnancy. J Am Coll Cardiol2017;
70: 426–435.
LinkMSBerkowLCKudenchukPJ, et al.
Part 7: adult advanced cardiovascular life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation2015;
132: S444–464.
185.
HoDSZecchinRPRichardsDA, et al.
Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet1994;
344: 18–23.
186.
GorgelsAPvan den DoolAHofsA, et al.
Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol1996;
78: 43–46.
187.
SombergJCBailinSJHaffajeeCI, et al.
Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol2002;
90: 853–859.
188.
TomlinsonDRCherianPBettsTR, et al.
Intravenous amiodarone for the pharmacological termination of haemodynamically-tolerated sustained ventricular tachycardia: is bolus dose amiodarone an appropriate first-line treatment?Emerg Med J2008;
25: 15–18.
BamanTSLangeDCIlgKJ, et al.
Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm2010;
7: 865–869.
191.
DabbaghGSBogunF.Predictors and therapy of cardiomyopathy caused by frequent ventricular ectopy. Curr Cardiol Rep2017;
19: 80.
192.
ConnollySJHallstromAPCappatoR, et al.
Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J2000;
21: 2071–2078.
193.
GuptaSFigueredoVM.Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management. Int J Cardiol2014;
172: 40–46.
194.
PageRL.Treatment of arrhythmias during pregnancy. Am Heart J1995;
130: 871–876.
195.
BrodineWNTungRTLeeJK, et al.
Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol2005;
96: 691–695.
196.
ExnerDVReiffelJAEpsteinAE, et al.
Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol1999;
34: 325–333.
197.
ChatterjeeSChaudhuriDVedanthanR, et al.
Early intravenous beta-blockers in patients with acute coronary syndrome – a meta-analysis of randomized trials. Int J Cardiol2013;
168: 915–921.
198.
SinghSNFletcherRDFisherSG, et al.
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med1995;
333: 77–82.
199.
KühlkampVMewisCMermiJ, et al.
Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol1999;
33: 46–52.
200.
SinghBNSinghSNRedaDJ, et al.
Amiodarone versus sotalol for atrial fibrillation. N Engl J Med2005;
352: 1861–1872.
201.
PicciniJPBergerJSO’ConnorCM.Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J2009;
30: 1245–1253.
202.
SinghSNFletcherRDFisherSG.Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. J Emerg Med1996;
1: 127–128.
203.
Investigators CASTCAST.Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med1989;
321: 406–412.
204.
ÁlvarezMBertomeu-GonzálezVArcochaMF, et al.
Nonfluoroscopic catheter ablation. Results from a prospective multicenter registry. Rev Esp Cardiol (Engl Ed)2017;
70: 699–705.
205.
PayneJLoMPaydakH, et al.
Near-zero fluoroscopy implantation of dual-chamber pacemaker in pregnancy using electroanatomic mapping. HeartRhythm Case Rep2017;
3: 205–209.
206.
Prolic KalinšekTJanMRuparK, et al.
Zero-fluoroscopy catheter ablation of concealed left accessory pathway in a pregnant woman. Europace2017;
19: 1384.
207.
TrompCHNanneACPernetPJ, et al.
Electrical cardioversion during pregnancy: safe or not. Neth Heart J2011;
19: 134–136.
208.
Pagan-CarloLASpencerKTRobertsonCE, et al.
Transthoracic defibrillation: importance of avoiding electrode placement directly on the female breast. J Am Coll Cardiol1996;
27: 449–452.
209.
NansonJElcockDWilliamsM, et al.
Do physiological changes in pregnancy change defibrillation energy requirements?Br J Anaesth2001;
87: 237–239.
210.
CasellaMRibattiVCattoV, et al.
Benefits of electroanatomic ablation of conventional cardiac arrhytmias: from fluoroscopy to zero X-ray mapping. Minerva Cardioangiol2018;
66: 49–62.
211.
McColloughCHSchuelerBAAtwellTD, et al.
Radiation exposure and pregnancy: when should we be concerned. Radiographics2007;
27: 909–917.
212.
DamilakisJTheocharopoulosNPerisinakisK, et al.
Conceptus radiation dose and risk from cardiac catheter ablation procedures. Circulation2001;
104: 893–897.
213.
KasparGSanamKGundlapalliS, et al.
Successful fluoroless radiofrequency catheter ablation of supraventricular tachycardia during pregnancy. Clin Case Rep2018;
6: 1334–1337.
214.
CasellaMDello RussoAPelargonioG, et al.
Near zerO fluoroscopic exPosure during catheter ablAtion of supRavenTricular arrhYthmias: the NO-PARTY multicentre randomized trial. Europace2016;
18: 1565–1572.
215.
ChenGSunGXuR, et al.
Zero-fluoroscopy catheter ablation of severe drug-resistant arrhythmia guided by Ensite NavX system during pregnancy: two case reports and literature review. Medicine (Baltimore)2016;
95: e4487.
216.
BigelowAMCraneSSKhouryFR, et al.
Catheter ablation of supraventricular tachycardia without fluoroscopy during pregnancy. Obstet Gynecol2015;
125: 1338–1341.
217.
TuzcuVGulEEErdemA, et al.
Cardiac interventions in pregnant patients without fluoroscopy. Pediatr Cardiol2015;
36: 1304–1307.
218.
RamanASSharmaSHariharanR.Minimal use of fluoroscopy to reduce fetal radiation exposure during radiofrequency catheter ablation of maternal supraventricular tachycardia. Tex Heart Inst J2015;
42: 152–154.
219.
KoźlukEGawrysiakMPiątkowskaA, et al.
Radiofrequency ablation without the use of fluoroscopy – in what kind of patients is it feasible?Arch Med Sci2013;
9: 821–825.
220.
TongCKiessMDeyellMW, et al.
Impact of frequent premature ventricular contractions on pregnancy outcomes. Heart2018;
104: 1370–1375.
221.
ErtekinEvan HagenIMSalamAM, et al.
Ventricular tachyarrhythmia during pregnancy in women with heart disease: data from the ROPAC, a registry from the European Society of Cardiology. Int J Cardiol2016;
220: 131–136.
222.
BircherCWFarrakhSGadaR.Supraventricular tachycardia presenting in labour: a case report achieving vaginal birth and review of the literature. Obstet Med2016;
9: 96–97.
